Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of FLT190 gene therapy in Fabry disease
2019-004645-32Phase 2Unknown
- Sponsor
- Freeline Therapeutics
- Start
- Dec 2019
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FLT190 in Fabry disease (FD), sponsored by Freeline Therapeutics. Primary endpoint: Adverse events by CTCAE v5.0. Status: unknown.
02
Drugs
FLT190
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2019-004645-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004645-32.